October #95 : New Meds On The Shelf - by Marissa Pareles

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

The Clock Watchers

After Ibn Zuhur

Stayin’ Alive: A Game Plan

I Wanna New Drug!

In Cold Blood

Unfine China

Maine Idea

Bayer's BIG Headache

Neg & Pos

Gone Shopping

The Bug Stops Here

Milestones

Documania

For Pete's Sake

Wake-Up Call

Heavenly & Hazardous

Shock and Blah

Publisher's Letter

Mailbox

O Lady Liberate:

O Cash up Front:

Tastes Great! Less Filling!

Tat Caveat

Only A Test

Lipodystrophy

New Meds On The Shelf

Book Report

60% of HIVers Now Survive Lymphoma

Zip Your Lipids

Tea Cells

Paris When It Sizzled

Playing It Safe And Sexy

HEP Or HIV?

The Soprano

Dementia

Butch And Moan

Toxic Avengers



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

October 2003

New Meds On The Shelf

by Marissa Pareles

Reyataz (atazanavir)
Bristol-Myers Squibb

Class: protease inhibitor (PI)    

Task: HIV suppression

Ticket: About $860 a month

Pros: The first once-daily PI, Reyataz seems not to raise lipids (cholesterol and triglycerides) as other PIs do, and it may avoid cross-resistance with other PIs, preserving future med choices when it’s used in a first-line combo.

Cons: Reyataz frequently caused jaundice (as many as 20 percent of cases in one trial), and may worsen hepatitis. You can’t combine it with many other drugs, including Viagra and indinavir (Crixivan). In rare cases, it causes heartbeat changes and lactic acid build-up in the blood.

An HIV vetern weighs in: Treatment activist Mike Barr: “The FDA data looked less promising than BMS’ claims. The longer we know Reyataz, the more it looks like other PIs—and it needs a ritonavir (Norvir) boost. Once you add this other PI, you may get the same old PI problems—heightened lipids.”


Emtriva (emtricitabine)
Gilead Sciences

Class: nucleoside reverse transcriptase inhibitor (nuke, or NRTI)

Task: HIV suppression

Ticket: About $340 a month

Pros: Can stand in for 3TC (Epivir), but you only need one dose a day. Gilead is currently testing a one-pill combo of Emtriva and tenofovir (Viread) for a two-nukes-in-one rival to Combivir. Fights hepatitis B, too.

Cons: Emtriva may not pack much punch for folks resistant to 3TC, since the resistance profiles are similar. Those with kidney problems need monitoring and dosing adjustments. Like other nukes, it may cause serious liver problems and lactic acid build-up in the blood.

An HIV Veteran weighs in: Barr: “The interesting thing here is that now Gilead has two one-a-days [Viread is the other] to reformulate together as one one-a-day.”
 



[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Are you buying holiday gifts that raise HIV/AIDS awareness?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.